RT Journal Article
SR Electronic
T1 Nine-month, all-oral regimens for rifampin-resistant tuberculosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.29.24301679
DO 10.1101/2024.01.29.24301679
A1 Guglielmetti, Lorenzo
A1 Khan, Uzma
A1 Velásquez, Gustavo E.
A1 Gouillou, Maelenn
A1 Abubakirov, Amanzhan
A1 Baudin, Elisabeth
A1 Berikova, Elmira
A1 Berry, Catherine
A1 Bonnet, Maryline
A1 Cellamare, Matteo
A1 Chavan, Vijay
A1 Cox, Vivian
A1 Dakenova, Zhanna
A1 de Jong, Bouke Catherine
A1 Ferlazzo, Gabriella
A1 Karabayev, Aydarkhan
A1 Kirakosyan, Ohanna
A1 Kiria, Nana
A1 Kunda, Mikanda
A1 Lachenal, Nathalie
A1 Lecca, Leonid
A1 McIlleron, Helen
A1 Motta, Ilaria
A1 Mucching-Toscano, Sergio
A1 Mushtaque, Hebah
A1 Nahid, Payam
A1 Oyewusi, Lawrence
A1 Panda, Samiran
A1 Patil, Sandip
A1 Phillips, Patrick
A1 Ruiz, Jimena
A1 Salahuddin, Naseem
A1 Sanchez-Garavito, Epifanio
A1 Seung, Kwonjune J.
A1 Ticona, Eduardo
A1 Trippa, Lorenzo
A1 Vargas, Dante
A1 Wasserman, Sean
A1 Rich, Michael L.
A1 Varaine, Francis
A1 Mitnick, Carole D.
YR 2024
UL http://medrxiv.org/content/early/2024/01/29/2024.01.29.24301679.abstract
AB Background After a history of poor treatments for rifampin-resistant tuberculosis (RR-TB), recent advances have resulted in shorter, more effective treatments. However, they are not available to everyone and have shortcomings, requiring additional treatment options.Methods endTB is an international, open-label, Phase 3 non-inferiority, randomized, controlled clinical trial to compare five 9-month all-oral regimens including bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C) and pyrazinamide (Z), to the standard (control) for treatment of fluoroquinolone-susceptible RR-TB. Participants were randomized to 9BLMZ, 9BCLLfxZ, 9BDLLfxZ, 9DCLLfxZ, 9DCMZ and control using Bayesian response-adaptive randomization. The primary outcome was favorable outcome at week 73 defined by two negative sputum culture results or by favorable bacteriologic, clinical and radiologic evolution. The non-inferiority margin was 12 percentage points.Results Of 754 randomized patients, 696 and 559 were included in the modified intention to treat (mITT) and per-protocol (PP) analyses, respectively. In mITT, the control had 80.7% favorable outcomes. Regimens 9BCLLfxZ [adjusted risk difference (aRD): 9.5% (95% confidence interval (CI), 0.4 to 18.6)], 9BLMZ [aRD: 8.8% (95%CI, −0.6 to 18.2)], and 9BDLLfxZ [3.9% (95%CI, −5.8 to 13.6)] were non-inferior in mITT and in PP. The proportion of participants experiencing grade 3 or higher adverse events was similar across the regimens. Grade 3 or higher hepatotoxicity occurred in 11.7% of the experimental regimens overall and in 7.1% of the control.Conclusions The endTB trial increases treatment options for RR-TB with three shortened, all-oral regimens that were non-inferior to a current well-performing standard of care.ClinicalTrials.gov:NCT02754765Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02754765Funding StatementThis study was funded by Unitaid.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committees/IRBs of Medecins Sans Frontieres, Harvard Medical School, Institute of Tropical Medicine Antwerp, Interactive Research and Development, and each participating site, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.